David S Collins
Overview
Explore the profile of David S Collins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
106
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dang X, Shih H, Sharma R, Angwin-Kaerner D, Lin K, Kapur S, et al.
Pharm Res
. 2024 Mar;
41(4):751-763.
PMID: 38443633
Purpose: To evaluate the clinical feasibility and tolerability of large volume subcutaneous delivery at different injection depths for lean and non-lean subjects. Methods: A single-center, randomized, subject-blinded, crossover study in...
2.
Zhong X, Veilleux J, Shi G, Collins D, Vlachos P, Ardekani A
Int J Pharm
. 2023 Apr;
640:122975.
PMID: 37116602
In recent years, significant progress has been made in the studies of the spring-driven autoinjector, leading to an improved understanding of this device and its interactions with tissue and therapeutic...
3.
Zhang Y, Dou Z, Veilleux J, Shi G, Collins D, Vlachos P, et al.
Int J Pharm
. 2021 Sep;
608:121062.
PMID: 34506926
The collapse of cavitation bubbles induced by abrupt acceleration of the syringe in an autoinjector device can lead to protein aggregation. The details of bubble dynamics are investigated using an...
4.
Shi G, Pisupati K, Parker J, Corvari V, Payne C, Xu W, et al.
Pharm Res
. 2021 May;
38(5):779-793.
PMID: 33942212
Purpose: The objective of this work was to systematically evaluate the effects of formulation composition on subcutaneous injection site pain (ISP) using matrices comprising of common pharmaceutical excipients. Methods: Two...
5.
Zhang Y, Han D, Dou Z, Veilleux J, Shi G, Collins D, et al.
Pharm Res
. 2021 Feb;
38(2):257-275.
PMID: 33619639
Purpose: Interface motion and hydrodynamic shear of the liquid slosh during the insertion of syringes upon autoinjector activation may damage the protein drug molecules. Experimentally validated computational fluid dynamics simulations...
6.
Shi G, Connor R, Collins D, Kang D
AAPS PharmSciTech
. 2021 Jan;
22(1):39.
PMID: 33409604
Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous (SC) delivery of co-administered therapeutic agents by locally and transiently degrading hyaluronan in the SC space, and can be administered with therapeutics using...
7.
Zhong X, Guo T, Vlachos P, Veilleux J, Shi G, Collins D, et al.
Int J Pharm
. 2020 Nov;
594:120008.
PMID: 33189808
This study focuses on developing a predictive dynamic model for spring-driven autoinjectors. The values of unknown physical parameters, such as the heat convection coefficient and the friction force between the...
8.
Dou Z, Eshraghi J, Guo T, Veilleux J, Duffy K, Shi G, et al.
Curr Med Res Opin
. 2020 Jun;
36(8):1343-1354.
PMID: 32544355
Autoinjectors are a convenient and efficient way to self-administer subcutaneous injections of biopharmaceuticals. Differences in device mechanical design can affect the autoinjector functionality and performance. This study investigates the performance...
9.
Collins D, Sanchez-Felix M, Badkar A, Mrsny R
J Control Release
. 2020 Feb;
321:475-482.
PMID: 32105759
Subcutaneous (SC) delivery of biotherapeutics is well established as a route of administration across many therapeutic areas and has been shown to be effective and well-tolerated. It can offer several...
10.
Park J, Park J, Castanares M, Collins D, Yeo Y
Mol Pharm
. 2019 Mar;
16(5):1864-1873.
PMID: 30916974
Tumor microenvironment is a significant physical barrier to the effective delivery of chemotherapy into solid tumors. To overcome this challenge, tumors are pretreated with an agent that reduces cellular and...